As cell therapies continue to advance, the need for better automated, large-scale manufacturing options increases.

LAST YEAR: NEW CHANGE: NA AGE: 75 RESIDENCE: Bel Air SOURCE OF WEALTH: Pharmaceutical company sales ...

Discover the top biotech companies pioneering the next healthcare breakthroughs. Learn how innovative firms are ...

Its investment in CAR-T drugs is part of that ambitious push, and 2017 is set to be a decisive year for Novartis and main rival, Kite Pharma, who lead this hugely promising but risky field.

Gilead Sciences' cell therapy Kite Pharma has bulked up its position in natural killer (NK) cell therapies, pledging up to $2.3 billion for a partnership with Shoreline Bioscience focusing on off ...

The US FDA has granted Kite’s Yescarta (axicabtagene ciloleucel) a Regenerative Medicine Advanced Therapy (RMAT) designation ...

This agreement seeks to strengthen the facilitation skills of coaches who work with Hispanic adolescents in vulnerable ...

Chinese multinational conglomerate Fosun International Limited is a global innovation-driven consumer group whose mission is ...

Catch up on all the biggest pharmaceutical industry news from September, including new appointments, mergers and acquisitions ...

The global CAR T-Cell Therapy Market is projected to reach more than USD 22.2 billion by 2032 from USD 2.1 billion in 2023, growing at a CAGR of 30% from 2024-2032. In addition to market positioning, ...

Incorporated in 1995, Mankind Pharma specialises in various therapeutic areas, offering products from antibiotics to gastrointestinal, cardiovascular, dermal, and erectile dysfunction medications.

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.